Research study Program year 2023 Source: CMS Open Payments

VIDAS TB IGRA NILOR Study

Research payments

$229,195

30 payments

Through program year 2023, $229,195 in research payments was reported against VIDAS TB IGRA NILOR Study, across 30 payments, paid by bioMerieux.

Paid by
bioMerieux
ClinicalTrials.gov
No trial number was reported for this study

By program year

2 rows
Year Kind Amount Payments
2023 Research $485 3
2022 Research $228,710 27

Breakdown

Who paid Research payments · program years 2022–2023
  1. bioMerieux $229,195 30 payments
Who received the money Research payments · program years 2022–2023
  1. Saint Louis University Organisation paid for research $152,559 18 payments
  2. Ohsu Hospital And Clinics Teaching hospital · OR $76,636 12 payments

Usually the institution or organisation running the study, not a person.

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

2 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record